Cited by 984Cannabis and Cannabinoid ResearchNeuroscience and Neuropharmacology ResearchPain Mechanisms and Treatments

The DOI matches its Crossref record; 349 of the 351 references it cites were found in a registry or an index.

Cannabinoids and the expanded endocannabinoid system in neurological disorders

Cristino, Luigia, Bisogno, Tiziana, Di Marzo, Vincenzo·2020·Nature Reviews Neurology

Open this paper in CoChat — free account

Abstract

Anecdotal evidence that cannabis preparations have medical benefits together with the discovery of the psychotropic plant cannabinoid Δ 9-tetrahydrocannabinol (THC) initiated efforts to develop cannabinoid-based therapeutics. These efforts have been marked by disappointment, especially in relation to the unwanted central effects that result from activation of cannabinoid receptor 1 (CB1), which have limited the therapeutic use of drugs that activate or inactivate this receptor. The discovery of CB2 and of endogenous cannabinoid receptor ligands (endocannabinoids) raised new possibilities for safe targeting of this endocannabinoid system. However, clinical success has been limited, complicated by the discovery of an expanded endocannabinoid system - known as the endocannabinoidome - that includes several mediators that are biochemically related to the endocannabinoids, and their receptors and metabolic enzymes. The approvals of nabiximols, a mixture of THC and the non-psychotropic cannabinoid cannabidiol, for the treatment of spasticity and neuropathic pain in multiple sclerosis, and of purified botanical cannabidiol for the treatment of otherwise untreatable forms of paediatric epilepsy, have brought the therapeutic use of cannabinoids and endocannabinoids in neurological diseases into the limelight. In this Review, we provide an overview of the endocannabinoid system and the endocannabinoidome before discussing their involvement in and clinical relevance to a variety of neurological disorders, including Parkinson disease, Alzheimer disease, Huntington disease, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, stroke, epilepsy and glioblastoma.

Integrity signals

Registry

Crossref · 10.1038/s41582-019-0284-z

Cites

349 of 349 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

Items 201–349 of 349

Endocannabinoid Degradation Inhibition Improves Neurobehavioral Function, Blood–Brain Barrier Integrity, and Neuroinflammation following Mild Traumatic Brain Injury
Katz, P. S., Sulzer, J. K., Impastato, R. A., Teng, S. X., Rogers, E., & Molina, P. E. (2014) · Journal of Neurotrauma · doi:10.1089/neu.2014.3508 · Cited by 97
An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis
Loría, F., Petrosino, S., Hernangómez, M., Mestre, L., Spagnolo, A., Correa, F., Marzo, V. D., Docagne, F., & Guaza, C. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.020 · Cited by 96
Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model
Echegoyen, J. C., Armstrong, C., Morgan, R. J., & Soltész, I. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.02.019 · Cited by 95
Astroglial CB1 cannabinoid receptors regulate leptin signaling in mouse brain astrocytes
Bosier, B., Bellocchio, L., Metna‐Laurent, M., Gómez, E. S., Matias, I., Hébert-Chatelain, É., Cannich, A., Maître, M., Lesté-Lasserre, T., Cardinal, P., et al. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.08.001 · Cited by 95
Genetic deletion of monoacylglycerol lipase leads to impaired cannabinoid receptor CB 1 R signaling and anxiety‐like behavior
Imperatore, R., Morello, G., Luongo, L., Taschler, U., Romano, R., Gregorio, D. D., Belardo, C., Maione, S., Marzo, V. D., & Cristino, L. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13267 · Cited by 94
Self-citation
Cannabidiol Reduces Brain Damage and Improves Functional Recovery After Acute Hypoxia-Ischemia in Newborn Pigs
Lafuente, H., Alvarez, F. J., Pazos, M. R., Alvarez, A. A., Rey-Santano, M. C., Mielgo, V., Murgia-Esteve, X., Hilario, E., & Martínez-Orgado, J. A. (2011) · Pediatric Research · doi:10.1203/pdr.0b013e3182276b11 · Cited by 94
Orexin-A represses satiety-inducing POMC neurons and contributes to obesity via stimulation of endocannabinoid signaling
Morello, G., Imperatore, R., Palomba, L., Finelli, C., Labruna, G., Pasanisi, F., Sacchetti, L., Buono, L., Piscitelli, F., Orlando, P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521304113 · Cited by 94
Self-citation
Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes
Liang, Y., Woodward, D. F., Guzman, V. M., Li, C., Scott, D. F., Wang, J. W., Wheeler, L. A., Garst, M. E., Landsverk, K., Sachs, G. M., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.142 · Cited by 93
TRPV1 in the Central Nervous System: Synaptic Plasticity, Function, and Pharmacological Implications
Edwards, J. G. (2014) · Springer eBooks · doi:10.1007/978-3-0348-0828-6_3 · Cited by 92
The Endocannabinoid 2-Arachidonoylglycerol Is Responsible for the Slow Self-Inhibition in Neocortical Interneurons
Marinelli, S., Pacioni, S., Bisogno, T., Marzo, V. D., Prince, D. A., Huguenard, J. R., & Bacci, A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0847-08.2008 · Cited by 92
Self-citation
Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation
Giacoppo, S., Bramanti, P., & Mazzon, E. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.06.015 · Cited by 92
Validating Antibodies to the Cannabinoid CB2 Receptor
Marchalant, Y., Brownjohn, P. W., Bonnet, A., Kleffmann, T., & Ashton, J. C. (2014) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155414530995 · Cited by 91
CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer’s Disease
Koppel, J. L., Vingtdeux, V., Marambaud, P., d’Abramo, C., Jimenez, H. T., Stauber, M., Friedman, R., & Davies, P. (2013) · Molecular Medicine · doi:10.2119/molmed.2013.00140.revised · Cited by 90
Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson's Disease
Navarrete, F., García‐Gutiérrez, M. S., Aracil-Fernández, A., Lanciego, J. L., & Manzanares, J. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0603-x · Cited by 90
Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis
Filippo, M. D., Pini, L. A., Pelliccioli, G. P., Calabresi, P., & Sarchielli, P. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.139071 · Cited by 89
PRECLINICAL STUDY: FULL ARTICLE: Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR‐α nuclear receptors
Luchicchi, A., Lecca, S., Carta, S., Pillolla, G., Muntoni, A. L., Yaşar, S., Goldberg, S. R., & Pistis, M. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00222.x · Cited by 88
Epigenetic Regulation of Fatty Acid Amide Hydrolase in Alzheimer Disease
D’Addario, C., Francesco, A. D., Arosio, B., Gussago, C., Dell’Osso, B. M., Bari, M., Galimberti, D., Scarpini, E. A., Altamura, A. C., Mari, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039186 · Cited by 87
Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice
Ahmad, A., Crupi, R., Impellizzeri, D., Campolo, M., Marino, A., Esposito, E., & Cuzzocrea, S. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.07.021 · Cited by 87
Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease
Bisogno, T., Martire, A., Petrosino, S., Popoli, P., & Marzo, V. D. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.06.031 · Cited by 86
Self-citation
The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG
Valdeolivas, S., Pazos, M. R., Bisogno, T., Piscitelli, F., Iannotti, F. A., Allarà, M., Sagredo, O., Marzo, V. D., & Fernández‐Ruíz, J. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.387 · Cited by 86
Self-citation
Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain
Brindisi, M., Maramai, S., Gemma, S., Brogi, S., Grillo, A., Di Cesare Mannelli, L., Gabellieri, E., Lamponi, S., Saponara, S., Gorelli, B., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01812 · Cited by 86
Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model
Khan, A. A., Shekh‐Ahmad, T., Khalil, A., Walker, M. C., & Ali, A. B. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14202 · Cited by 86
The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model
Fernández‐Suárez, D., Celorrio, M., Riezu‐Boj, J. I., Ugarte, A., Pacheco, R., González, H., Oyarzábal, J., Hillard, C. J., Franco, R., & Aymerich, M. S. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.05.021 · Cited by 85
Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory response in APdE9 mice and in adult mouse glial cells
Pihlaja, R., Helin, J. S., Eskola, O., Vasara, J., Lopez‐Picon, F. R., Haaparanta‐Solin, M., & Rinne, J. O. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0305-9 · Cited by 85
Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity
Keating, G. M. (2017) · Drugs · doi:10.1007/s40265-017-0720-6 · Cited by 85
Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients
Pisani, V., Moschella, V., Bari, M., Fezza, F., Galati, S., Bernardi, G., Stanzione, P., Pisani, A., & Maccarrone, M. (2010) · Movement Disorders · doi:10.1002/mds.23014 · Cited by 84
Opposing Control of Cannabinoid Receptor Stimulation on Amyloid-β-Induced Reactive Gliosis: In Vitro and in Vivo Evidence
Esposito, G., Iuvone, T., Savani, C., Scuderi, C., Filippis, D. D., Papa, M., Marzo, V. D., & Steardo, L. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121566 · Cited by 83
Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of SOD 1G93A Transgenic Mice and Evaluation of a Sativex®‐like Combination of Phytocannabinoids: Interest for Future Therapies in Amyotrophic Lateral Sclerosis
Moreno‐Martet, M., Espejo‐Porras, F., Fernández‐Ruíz, J., & de Lago, E. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12262 · Cited by 83
Type-1 Cannabinoid Receptor Activity During Alzheimer's Disease Progression
Manuel, I., Román, E. G. D. S., Giralt, M. T., Ferrer, I., & Rodríguez‐Puertas, R. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140492 · Cited by 82
Neurosurgery for Obsessive-Compulsive Disorder: Problems With Comorbidity
Albucher, R. C., Curtis, G. C., & Pitts, K. P. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.3.495a · Cited by 82
Cannabinoid-Mediated Inhibition of Recurrent Excitatory Circuitry in the Dentate Gyrus in a Mouse Model of Temporal Lobe Epilepsy
Bhaskaran, M. D., & Smith, B. N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010683 · Cited by 82
Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease
Sagredo, O., Pazos, M. R., Valdeolivas, S., & Fernández‐Ruíz, J. (2011) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488912798842278 · Cited by 82
β−Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR‐α, PPAR‐γ and TRPV1, but not CB1 or CB2 receptors
Benito, C., Tolón, R. M., Castillo, A. I., Ruiz‐Valdepeñas, L., Martínez-Orgado, J. A., Fernández, J., Vázquez, C., Cravatt, B. F., & Romero, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01889.x · Cited by 81
Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice
Rahimi, A., Faizi, M., Talebi, F., Noorbakhsh, F., Kahrizi, F., & Naderi, N. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.030 · Cited by 81
Predominant expression of lysosomal N-acylethanolamine-hydrolyzing acid amidase in macrophages revealed by immunochemical studies
Tsuboi, K., Zhao, L.-Y., Okamoto, Y., Araki, N., Ueno, M., Sakamoto, H., & Ueda, N. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.03.005 · Cited by 79
Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimer’s Disease Patients as a Potential Protective Mechanism against Neurodegenerative Decline
Altamura, C., Ventriglia, M., Martini, M. G., Montesano, D., Errante, Y., Piscitelli, F., Scrascia, F., Quattrocchi, C. C., Palazzo, P., Seccia, S., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142349 · Cited by 77
Involvement of transient receptor potential vanilloid type 1 channels in the pro-convulsant effect of anandamide in pentylenetetrazole-induced seizures
Manna, S. S. S., & Umathe, S. N. (2012) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.02.003 · Cited by 77
Acute Effects of a Selective Cannabinoid-2 Receptor Agonist on Neuroinflammation in a Model of Traumatic Brain Injury
Elliott, M. B., Tuma, R. F., Amenta, P. S., Barbe, M. F., & Jallo, J. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2010.1672 · Cited by 77
Effects of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole-induced seizure and electroencephalographic activity in rats
Vilela, L., Medeiros, D. D. C., Rezende, G. H. D. S. E., de Oliveira, A. C. P., Moraes, M. F. D., & Moreira, F. A. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.11.006 · Cited by 77
Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract
Verhoeckx, K. C. M., Voortman, T., Balvers, M. G. J., Hendriks, H., Wortelboer, H. M., & Witkamp, R. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.07.008 · Cited by 77
Treatment of Tourette’s Syndrome With Delta-9-Tetrahydrocannabinol
LLER-VAHL, K. R. M. ⁄., Schneider, U., KOLBE, H., & Emrich, H. M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.3.495 · Cited by 77
Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex
Lee, J. H., Agacinski, G., Williams, J. H., Wilcock, G. K., Esiri, M. M., Francis, P. T., Wong, P. T. ‐., Chen, C., & Lai, M. K. P. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.10.010 · Cited by 76
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders
de Lago, E., Fernández‐Ruíz, J., Ortega‐Gutiérrez, S., Cabranes, A., Pryce, G., Baker, D., López-Rodríguez, M. L., & Ramos, J. A. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.06.001 · Cited by 76
Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity
Zhao, P., Ignacio, S., Beattie, E. C., & Abood, M. E. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06041.x · Cited by 75
Effects of tetrahydrocannabinol on balance and gait in patients with dementia: A randomised controlled crossover trial
van den Elsen, G. A. H., Tobben, L., Ahmed, A. I. A., Verkes, R. J., Kramers, C., Marijnissen, R. M., Rikkert, M. G. M. O., & van der Marck, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116665357 · Cited by 75
Cannabinoids for Treatment of Dystonia in Huntington’s Disease
Carsten Saft, C., Hein, S., Lücke, T., Thiels, C., Peball, M., Djamshidian, A., Heim, B., & Seppi, K. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170283 · Cited by 75
Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis
Wen, J., Ribeiro, R., Tanaka, M., & Zhang, Y. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.010 · Cited by 74
The cannabinoid receptor agonist nabilone for the treatment of dementia‐related agitation
Passmore, M. J. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1828 · Cited by 74
Anti-inflammatory activity on compounds obtained from egg yolk, peanut oil, and soybean lecithin.
Ganley, O. H., Graessle, O. E., & Robinson, H. J. (1958) · PubMed · Cited by 74
Role of PPAR γ in the Differentiation and Function of Neurons
Quintanilla, R. A., Utreras, E., & Cabezas-Opazo, F. (2014) · PPAR Research · doi:10.1155/2014/768594 · Cited by 71
Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy
Palma, E., Reyes‐Ruiz, J. M., Lopergolo, D., Roseti, C., Bertollini, C., Ruffolo, G., Cifelli, P., Onesti, E., Limatola, C., Miledi, R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600251113 · Cited by 71
In vivo type 1 cannabinoid receptor availability in Alzheimer's disease
Ahmad, R. U., Goffin, K. E., den Stock, J. V., Winter, F. D., Cleeren, E., Bormans, G. M., Tournoy, J., Persoons, P., Laere, K. V., & Vandenbulcke, M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.002 · Cited by 70
Transient increase of interleukin-1β after prolonged febrile seizures promotes adult epileptogenesis through long-lasting upregulating endocannabinoid signaling
Feng, B., Tang, Y., Chen, B., Xu, C., Wang, Y., Dai, Y., Wu, D., Zhu, J., Wang, S., Zhou, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep21931 · Cited by 70
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson’s disease
Celorrio, M., Fernández‐Suárez, D., Rojo-Bustamante, E., Echeverry‐Alzate, V., Ramírez, M. J., Hillard, C. J., López‐Moreno, J. A., Maldonado, R. J., Oyarzábal, J., Franco, R., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.06.010 · Cited by 68
Inhibition of fatty acid amide hydrolase unmasks CB1receptor and TRPV1 channel‐mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal grey
Kawahara, H., Drew, G., Christie, M., & Vaughan, C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01157.x · Cited by 67
Alteration of endocannabinoid system in human gliomas
Wu, X.-Y., Han, L., Zhang, X., Li, L., Jiang, C., Qiu, Y., Huang, R., Xie, B., Lin, Z., Ren, J., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07625.x · Cited by 67
Treatment of Tourette syndrome with cannabinoids.
Müller‐Vahl, K. (2013) · PubMed · doi:10.3233/ben-120276 · Cited by 66
Worsening of Huntington disease phenotype in CB1 receptor knockout mice
Mievis, S., Blum, D. L., & Ledent, C. A. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.03.006 · Cited by 65
Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia
Schomacher, M., Müller, H. D., Sommer, C., Schwab, S., & Schäbitz, W. (2008) · Brain Research · doi:10.1016/j.brainres.2008.09.019 · Cited by 65
Oleoylethanolamide increases the expression of PPAR-Α and reduces appetite and body weight in obese people: A clinical trial
Payahoo, L., Khajebishak, Y., Barzegari, A., Alipour, S., Jafarabadi, M. A., Farrin, N., & Alireza, O. (2018) · Appetite · doi:10.1016/j.appet.2018.05.129 · Cited by 65
Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders
Espejo‐Porras, F., Piscitelli, F., Verde, R., Ramos, J. A., Marzo, V. D., de Lago, E., & Fernández‐Ruíz, J. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9602-4 · Cited by 62
Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome
Abi‐Jaoude, E., Chen, L., Cheung, P., Bhikram, T., & Sandor, P. (2017) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.16110310 · Cited by 62
Resolution of inflammation is altered in chronic heart failure and entails a dysfunctional responsiveness of T lymphocytes
Chiurchiù, V., Leuti, A., Saracini, S., Fontana, D. O., Finamore, P., Giua, R., Padovini, L., Incalzi, R. A., & Maccarrone, M. (2018) · The FASEB Journal · doi:10.1096/fj.201801017r · Cited by 62
Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes
Battista, N., Bari, M., Tarditi, A., Mariotti, C., Bachoud‐Lévi, A., Zuccato, C., Finazzi‐Agrò, A., Genitrini, S., Peschanski, M., Donato, S. D., et al. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.04.012 · Cited by 60
Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer’s Disease:In VitroandIn VivoEvidence
Bronzuoli, M. R., Facchinetti, R., Steardo, L., Romano, A., Stecca, C., Passarella, S., Steardo, L., Cassano, T., & Scuderi, C. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/4720532 · Cited by 60
A model of cost-outcome analysis for assistive technology
Andrich, R., Ferrario, M., & Moi, M. (1998) · Disability and Rehabilitation · doi:10.3109/09638289809166850 · Cited by 59
Chronic oleoylethanolamide treatment improves spatial cognitive deficits through enhancing hippocampal neurogenesis after transient focal cerebral ischemia
Yang, L., Guo, H., Zhou, H., Suo, D., Li, W., Zhou, Y., Zhao, Y., Yang, W., & Jin, X. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.02.012 · Cited by 59
Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas
de Jesús, M. L., Hostalot, C., Garibi, J., Sallés, J., Meana, J. J., & Callado, L. F. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.03.007 · Cited by 59
Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis
Rajan, T. S., Scionti, D., Diomede, F., Grassi, G., Pollastro, F., Piattelli, A., Cocco, L., Bramanti, P., Mazzon, E., & Trubiani, O. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25757 · Cited by 59
Targeting brain and peripheral plasticity of the lipidome in acute kainic acid-induced epileptic seizures in mice via quantitative mass spectrometry
Lerner, R., Post, J. M., Loch, S., Lutz, B., & Bîndilă, L. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.11.008 · Cited by 59
Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple Sclerosis
Orefice, N. S., Alhouayek, M., Carotenuto, A., Montella, S., Barbato, F., Comelli, A., Calignano, A., Muccioli, G. G., & Orefice, G. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0420-z · Cited by 58
Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
Brotini, S., Schievano, C., & Guidi, L. (2017) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527316666170321124949 · Cited by 57
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)
Messina, S., Solaro, C. M., Righini, I., Bergamaschi, R., Bonavita, S., Bossio, R. B., Morra, V. B., Costantino, G., Cavalla, P., Centonze, D., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180651 · Cited by 57
Cannabinoid Signaling in Glioma Cells
Ellert‐Miklaszewska, A., Ciechomska, I. A., & Kamińska, B. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-4719-7_11 · Cited by 57
Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism
Morales, P., Goya, P., & Jagerovic, N. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.031 · Cited by 55
The Novel Endocannabinoid Receptor GPR18 Is Expressed in the Rostral Ventrolateral Medulla and Exerts Tonic Restraining Influence on Blood Pressure
Penumarti, A., & Abdel‐Rahman, A. A. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.209213 · Cited by 54
Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS
Pasquarelli, N., Engelskirchen, M., Hanselmann, J., Endres, S., Porazik, C., Bayer, H., Buck, E., Karsak, M., Weydt, P., Ferger, B., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.03.037 · Cited by 54
Inhibition of Endocannabinoid Degradation Improves Outcomes from Mild Traumatic Brain Injury: A Mechanistic Role for Synaptic Hyperexcitability
Mayeux, J. P., Katz, P. S., Edwards, S., Middleton, J. W., & Molina, P. E. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2016.4452 · Cited by 53
Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat
Walsh, S., Mnich, K., Mackie, K., Gorman, A. M., Finn, D. P., & Dowd, E. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.01.009 · Cited by 52
Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271
Mauler, F., Hinz, V. C., Augstein, K.-H., Faßbender, M., & Horváth, E. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03376-6 · Cited by 51
Endocannabinoid regulation of amyloid-induced neuroinflammation
Vázquez, C., Tolón, R. M., Grande, M. T., Caraza, M., Moreno, M., Koester, E. C., Villaescusa, B., Ruiz‐Valdepeñas, L., Fernández, J., Cravatt, B. F., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.003 · Cited by 50
Possible Anandamide and Palmitoylethanolamide involvement in human stroke
Naccarato, M., Pizzuti, D., Petrosino, S., Simonetto, M., Ferigo, L., Grandi, F., Pizzolato, G., & Marzo, V. D. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-47 · Cited by 49
siRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycine-induced cell migration
McHugh, D., Wager‐Miller, J., Page, J., & Bradshaw, H. B. (2012) · Journal of Molecular Signaling · doi:10.1186/1750-2187-7-10 · Cited by 49
N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice
Donvito, G., Piscitelli, F., Muldoon, P. P., Jackson, A. B., Vitale, R. M., D’Aniello, E., Giordano, C., Ignatowska-Jankowska, B. M., Mustafa, M. A., Guida, F., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.03.020 · Cited by 49
Transient Receptor Potential Vanilloid 1 Modulates Central Inflammation in Multiple Sclerosis
Bassi, M. S., Gentile, A., Iezzi, E., Zagaglia, S., Musella, A., Simonelli, I., Gilio, L., Furlan, R., Finardi, A., Marfia, G. A., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00030 · Cited by 49
Cannabinoid CB1 Receptors are Early DownRegulated Followed by a Further UpRegulation in the Basal Ganglia of Mice with Deletion of Specific Park Genes
Garcı́a-Arencibia, M., García, C., Kurz, A., Rodríguez‐Navarro, J. A., Gispert-Sánchez, S., Mena, M. A., Auburger, G. W. J., de Yébenes, J. G., & Fernández‐Ruíz, J. (2009) · Springer eBooks · doi:10.1007/978-3-211-92660-4_22 · Cited by 48
Involvement of central TRPV1 receptors in pentylenetetrazole and amygdala-induced kindling in male rats
Shirazi, M., Izadi, M., Amin, M., Rezvani, M. E., Roohbakhsh, A., & Shamsizadeh, A. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1689-5 · Cited by 48
Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation
Russo, M., Calabrò, R. S., Naro, A., Sessa, E., Rifici, C., D’Aleo, G., Leo, A., Luca, R. D., Quartarone, A., & Bramanti, P. (2015) · Neural Plasticity · doi:10.1155/2015/656582 · Cited by 48
Involvement of nitrergic system in the anticonvulsant effect of the cannabinoid CB1 agonist ACEA in the pentylenetetrazole-induced seizure in mice
Bahremand, A., Nasrabady, S. E., Shafaroodi, H., Ghasemi, M., & Dehpour, A. R. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.01.003 · Cited by 47
Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis
Hilliard, A., Stott, C. G., Wright, S., Guy, G. W., Pryce, G., Al‐Izki, S., Bolton, C., & Giovannoni, G. (2012) · ISRN Neurology · doi:10.5402/2012/802649 · Cited by 46
Anti-excitotoxic effects of cannabidiol are partly mediated by enhancement of NCX2 and NCX3 expression in animal model of cerebral ischemia
Khaksar, S., & Bigdeli, M. R. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.011 · Cited by 46
AM1241 alleviates MPTP-induced Parkinson's disease and promotes the regeneration of DA neurons in PD mice
Shi, J., Cai, Q., Zhang, J., He, X., Liu, Y., Zhu, R., & Jin, L. (2017) · Oncotarget · doi:10.18632/oncotarget.18871 · Cited by 46
Alleviation of Neuropathology by Inhibition of Monoacylglycerol Lipase in APP Transgenic Mice Lacking CB2 Receptors
Zhang, J., & Chen, C. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0689-x · Cited by 45
In vitro and in vivo models of H untington's disease show alterations in the endocannabinoid system
Bari, M., Battista, N., Valenza, M., Mastrangelo, N., Malaponti, M., Catanzaro, G., Centonze, D., Finazzi‐Agrò, A., Cattaneo, E. F., & Maccarrone, M. (2013) · FEBS Journal · doi:10.1111/febs.12329 · Cited by 44
N -arachidonoyl-L-serine (AraS) Possesses Proneurogenic Properties in Vitro and in Vivo after Traumatic Brain Injury
Cohen‐Yeshurun, A., Willner, D., Trembovler, V., Alexandrovich, A. G., Mechoulam, R., Shohami, E., & Leker, R. R. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.75 · Cited by 44
Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: a longitudinal study in multiple sclerosis patients
Sánchez, A., Román-Vega, L., Ramil, E., Giuffrida, A., & Garcı́a-Merino, A. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12443 · Cited by 43
Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials
Turri, M., Teatini, F., Donato, F., Zanette, G., Tugnoli, V., Deotto, L., Bonetti, B., & Squintani, G. M. (2018) · Medicines · doi:10.3390/medicines5030059 · Cited by 43
Gut microbiota, cannabinoid system and neuroimmune interactions: New perspectives in multiple sclerosis
Mestre, L., Carrillo-Salinas, F. J., Mecha, M., Feliú, A., & Guaza, C. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.08.037 · Cited by 43
Pro-epileptic effects of the cannabinoid receptor antagonist SR141716 in a model of audiogenic epilepsy
Vinogradova, L. V., Shatskova, A. B., & van Rijn, C. M. (2011) · Epilepsy Research · doi:10.1016/j.eplepsyres.2011.06.007 · Cited by 40
Involvement of PPAR receptors in the anticonvulsant effects of a cannabinoid agonist, WIN 55,212-2
Payandemehr, B., Ebrahimi, A., Gholizadeh, R., Rahimian, R., Varastehmoradi, B., Gooshe, M., Aghaei, H., Mousavizadeh‬, K., & Dehpour, A. R. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.11.005 · Cited by 40
Post-status epilepticus treatment with the cannabinoid agonist WIN 55,212-2 prevents chronic epileptic hippocampal damage in rats
Maio, R. D., Cannon, J. R., & Greenamyre, J. T. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.10.018 · Cited by 40
The Endocannabinoid System: A Putative Role in Neurodegenerative Diseases
Iorio, G. D., Lupi, M., Sarchione, F., Matarazzo, I., Santacroce, R., Petruccelli, F., Martinotti, G., & Giannantonio, M. D. (2013) · international journal high risk behaviors & addiction · doi:10.5812/ijhrba.9222 · Cited by 39
Emerging Role of Diet and Microbiota Interactions in Neuroinflammation
Janakiraman, M., & Krishnamoorthy, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02067 · Cited by 39
The endocannabinoidome : the world of endocannabinoids and related mediators
Marzo, V. D., & Wang, J. Y. (2015) · Cited by 38
Neuroprotective Potential of Adenosine A2Aand Cannabinoid CB1Receptor Antagonists in an Animal Model of Parkinson Disease
Cerri, S., Levandis, G., Ambrosi, G., Montepeloso, E., Antoninetti, G., Franco, R., Lanciego, J. L., Baqi, Y., Müller, C. E., Pinna, A., et al. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000064 · Cited by 38
Structure of Cannabinol. I. Preparation of an Isomer, 3-Hydroxy-1-n-amyl-6,6,9-trimethyl-6-dibenzopyran
ADAMS, R. L. P., Pease, D. C., Clark, J. H., & Baker, B. R. (1940) · Journal of the American Chemical Society · doi:10.1021/ja01865a081 · Cited by 38
Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity
Dopart, R., Lu, D., Lichtman, A. H., & Kendall, D. A. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1428342 · Cited by 38
Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors
Pryce, G., Cabranes, A., Fernández‐Ruíz, J., Bisogno, T., Marzo, V. D., Long, J. Z., Cravatt, B., Giovannoni, G., & Baker, D. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513485982 · Cited by 37
Self-citation
Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233
Gurley, S. N., Abidi, A. H., Allison, P. B., Guan, P., Duntsch, C. D., Robertson, J. H., Kosanke, S. D., Keir, S. T., Bigner, D. D., Elberger, A. J., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0958-5 · Cited by 37
Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors
Aghaei, I., Rostampour, M., Shabani, M., Naderi, N., Motamedi, F., Babaei, P., & Khakpour-Taleghani, B. (2015) · Epilepsy Research · doi:10.1016/j.eplepsyres.2015.08.010 · Cited by 37
A CB1/CB2 receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin
Arévalo‐Martín, Á., Molina‐Holgado, E., & Guaza, C. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.012 · Cited by 36
A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity
Marinelli, L., Balestrino, M., Mori, L., Puce, L., Rosa, G. M., Giorello, L., Currà, A., Fattapposta, F., Serrati, C., Gandolfo, C., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016843 · Cited by 36
Inhibition of Transient Receptor Potential Vanilloid 1 Attenuates Blood–Brain Barrier Disruption after Traumatic Brain Injury in Mice
Yang, D., Yao, J., Liu, Y., Xu, Z., Yuan, F., Wang, M.-L., Geng, Z., & Tian, H. (2018) · Journal of Neurotrauma · doi:10.1089/neu.2018.5942 · Cited by 36
Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease
Pietropaolo, S., Bellocchio, L., Ruiz-Calvo, A., Cabanas, M., Du, Z., Guzmán, M., Garret, M., & Cho, Y. H. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.021 · Cited by 34
Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice
Cabranes, A., Pryce, G., Baker, D., & Fernández‐Ruíz, J. (2006) · Brain Research · doi:10.1016/j.brainres.2006.06.001 · Cited by 34
Pre- and postsynaptic type-1 cannabinoid receptors control the alterations of glutamate transmission in experimental autoimmune encephalomyelitis
Musella, A., Sepman, H., Mandolesi, G., Gentile, A., Fresegna, D., Haji, N., Conrad, A., Lutz, B., Maccarrone, M., & Centonze, D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.01.007 · Cited by 33
Amyotrophic Lateral Sclerosis Treatment with Ultramicronized Palmitoylethanolamide: A Case Report
Clemente, S. (2012) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311201070933 · Cited by 32
Attenuation of kainic acid-induced status epilepticus by inhibition of endocannabinoid transport and degradation in guinea pigs
Shubina, L., Алиев, Р. Р., & Kitchigina, V. F. (2015) · Epilepsy Research · doi:10.1016/j.eplepsyres.2015.01.003 · Cited by 31
Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice
Łuszczki, J. J., Właź, A., Karwan, S., Florek-Łuszczki, M., & Czuczwar, S. J. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.10.020 · Cited by 31
Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients
Espejo‐Porras, F., Fernández‐Ruíz, J., & de Lago, E. (2018) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2018.1425454 · Cited by 31
Increased tonic cannabinoid CB1R activity and brain region-specific desensitization of CB1R Gi/o signaling axis in mice with global genetic knockout of monoacylglycerol lipase
Navia‐Paldanius, D., Aaltonen, N., Lehtonen, M., Savinainen, J. R., Taschler, U., Radner, F. P. W., Zimmermann, R., & Laitinen, J. T. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.06.005 · Cited by 30
The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia
Rojo-Bustamante, E., Abellanas, M. A., Clavero, P., Thiolat, M.-L., Li, Q., Luquín, M. R., Bézard, E., & Aymerich, M. S. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.06.019 · Cited by 30
Δ9-tetrahydrocannabinol (Δ9-THC) prevents cerebral infarction via hypothalamic-independent hypothermia
Hayakawa, K., Mishima, K., Nozako, M., Hazekawa, M., Ogata, A., Fujioka, M., Harada, K., Mishima, S., Orito, K., Egashira, N., et al. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.01.014 · Cited by 28
Modulation of monocytes by bioactive lipid anandamide in multiple sclerosis involves distinct Toll-like receptors
Chiurchiù, V., Leuti, A., Cencioni, M. T., Albanese, M., Bardi, M. D., Bisogno, T., Centonze, D., Battistini, L., & Maccarrone, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.003 · Cited by 28
Self-citation
Pathway-Specific Control of Striatal Neuron Vulnerability by Corticostriatal Cannabinoid CB1 Receptors
Ruiz-Calvo, A., Maroto, I. B., Bajo‐Grañeras, R., Chiarlone, A., Gaudioso, Á., Ferrero, J. J., Resel, E., Sánchez‐Prieto, J., Rodríguez‐Navarro, J. A., Marsicano, G., et al. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx285 · Cited by 28
Disease‐Modifying Effects of RHC 80267 and JZL 184 in a Pilocarpine Mouse Model of Temporal Lobe Epilepsy
Ma, L., Wang, L., Yang, F., Meng, X., Wu, C., Ma, H., & Jiang, W. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12302 · Cited by 27
Early alteration of distribution and activity of hippocampal type-1 cannabinoid receptor in Alzheimer’s disease-like mice overexpressing the human mutant amyloid precursor protein
Maccarrone, M., Totaro, A., Leuti, A., Giacovazzo, G., Scipioni, L., Mango, D., Coccurello, R., Nisticò, R., & Oddi, S. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.009 · Cited by 27
Anticonvulsive effects of endocannabinoids; an investigation to determine the role of regulatory components of endocannabinoid metabolism in the Pentylenetetrazol induced tonic- clonic seizures
Zareie, P., Sadegh, M., Palizvan, M. R., & Moradi‐Chameh, H. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0195-5 · Cited by 27
Studies on the agonistic activity of delta 9-11-tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with delta 9-tetrahydrocannabinol.
Beardsley, P. M., Scimeca, J. A., & Martin, B. R. (1987) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-5347(25)00275-7 · Cited by 26
Cannabis-based treatment induces polarity-reversing plasticity assessed by theta burst stimulation in humans
Koch, G., Mori, F., Codecà, C., Kusayanagi, H., Monteleone, F., Buttari, F., Fiore, S., Bernardi, G., & Centonze, D. (2009) · Brain stimulation · doi:10.1016/j.brs.2009.03.001 · Cited by 25
Early increase of cannabinoid receptor density after experimental traumatic brain injury in the newborn piglet
Donat, C. K., Fischer, F., Walter, B. L., Deuther‐Conrad, W., Brodhun, M., Bauer, R., & Brust, P. (2014) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2014-1985 · Cited by 24
Long-term disease-modifying effect of the endocannabinoid agonist WIN55,212-2 in a rat model of audiogenic epilepsy
Vinogradova, L. V., & van Rijn, C. M. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.12.002 · Cited by 23
Clinical use of dronabinol.
Plasse, T. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.11.2079 · Cited by 19
CB1 receptor antagonism prevents long-term hyperexcitability after head injury by regulation of dynorphin-KOR system and mGluR5 in rat hippocampus
Wang, X., Wang, Y., Zhang, C., Liu, C., Zhao, B., Wei, N., Zhang, J., & Zhang, K. (2016) · Brain Research · doi:10.1016/j.brainres.2016.05.055 · Cited by 19
Post-transcriptional regulation of 5'-untranslated regions of human Transient Receptor Potential Vanilloid type-1 (TRPV-1) channels: role in the survival of glioma patients
Nabissi, M., Morelli, M. B., Arcella, A., Cardinali, C., Santoni, M., Bernardini, G., Santoni, A., Santoni, G., & Amantini, C. (2016) · Oncotarget · doi:10.18632/oncotarget.13132 · Cited by 19
Effects of Cannabinoid Receptor Agonist WIN 55,212-2 on Blood-Brain Barrier Disruption in Focal Cerebral Ischemia in Rats
CHI, O. Z., Barsoum, S., Grayson, J., Hunter, C., Liu, X., & Weiss, H. R. (2012) · Pharmacology · doi:10.1159/000338755 · Cited by 18
Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex®
Carotenuto, A., Iodice, R., Petracca, M., Inglese, M., Cerillo, I., Cocozza, S., Saiote, C., Brunetti, A., Tedeschi, E., Manganelli, F., et al. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12660 · Cited by 18
Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis
Sorosina, M., Clarelli, F., Ferrè, L., Osiceanu, A., Unal, N., Mascia, E., Martinelli, V., Comi, G., Benigni, F., Esposito, F., et al. (2018) · European Journal of Neurology · doi:10.1111/ene.13623 · Cited by 18
Surprising outcomes in cannabinoid CB1/CB2 receptor double knockout mice in two models of ischemia
Ward, S. J., Castelli, F., Reichenbach, Z. W., & Tuma, R. F. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.12.030 · Cited by 17
The level of evidence of medical marijuana use for treating disabilities: a scoping review
Stetten, N. E., Pomeranz, J. L., Moorhouse, M. D., Yurasek, A. M., & Blue, A. V. (2018) · Disability and Rehabilitation · doi:10.1080/09638288.2018.1523952 · Cited by 16
Functional Autoradiography Shows Unaltered Cannabinoid CB1 Receptor Signalling in Hippocampus and Cortex of APP/PS1 Transgenic Mice
Kärkkäinen, E., Tanila, H., & Laitinen, J. T. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311211080014 · Cited by 11
Techniques for the Cellular and Subcellular Localization of Endocannabinoid Receptors and Enzymes in the Mammalian Brain
Cristino, L., Imperatore, R., & Marzo, V. D. (2017) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2017.05.003 · Cited by 9
Self-citation
Cannabinoid CB 1 receptors are early DownRegulated followed by a further UpRegulation in the basal Ganglia of mice with deletion of specific park genes
Garcı́a-Arencibia, M., Román, C., Kurz, A., Rodríguez‐Navarro, J. A., Gispert-Sánchez, S., Mena, M. A., Auburger, G. W. J., de Yébenes, J. G., & Fernández‐Ruíz, J. (2009) · doi:10.1007/978-3-211-92660-4-22 · Cited by 9
Dedications
Marzo, V. D., & Wang, J. Y. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-420126-2.00018-3 · Cited by 9
Investigational cannabinoids in seizure disorders, what have we learned thus far?
Zečević, D. R., Folić, M., Tantoush, Z., Radovanović, M., Babić, G. M., & Јаnkovic, S. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1482275 · Cited by 8
Endocannabinoid Role in Synaptic Plasticity and Learning
Lutz, B., & Marsicano, G. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.00816-0 · Cited by 7
Medical cannabis: A needs analysis for people with epilepsy
Kerai, A., Sim, T. F., & Emmerton, L. (2018) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2018.08.003 · Cited by 6
Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice
Bilsland, L., Dick, J. R. T., Pryce, G., Petrosino, S., Marzo, V. D., Baker, D., & Greensmith, L. (2006) · UCL Discovery (University College London) · Cited by 5
From Nose to Gut - The Role of the Microbiome in Neurological Disease.
Bell, J. S., Spencer, J., Yates, R., Yee, S. T., Jacobs, B. M., & DeLuca, G. C. (2018) · Neuropathology and Applied Neurobiology · Cited by 4

Sorted by citations

Gut microbiome and health: mechanistic insights
de Vos, W. M., Tilg, H., Van Hul, M., & Cani, P. D. (2022) · Gut · doi:10.1136/gutjnl-2021-326789 · Cited by 2,388
Signalling cognition: The gut microbiota and hypothalamic-pituitary-adrenal axis
Rusch, J. A., Layden, B. T., & Dugas, L. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1130689 · Cited by 415
Bioactive lipids, inflammation and chronic diseases
Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.028 · Cited by 376
The effects of microglia-associated neuroinflammation on Alzheimer’s disease
Wang, C., Zong, S., Cui, X., Wang, X., Wu, S., Wang, L., Liu, Y., & Lu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117172 · Cited by 331
Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals
Legare, C. A., Raup‐Konsavage, W. M., & Vrana, K. E. (2022) · Pharmacology · doi:10.1159/000521683 · Cited by 320

See all 984

Authors: Cristino, L., Bisogno, T., & Di Marzo, V.
Affiliations: Istituto di Chimica Biomolecolare (IT)
Istituto di Farmacologia Traslazionale (IT)
ORCID: Cristino, Luigia
Bisogno, Tiziana
Di Marzo, Vincenzo
Venue: Nature Reviews Neurology
Publisher: Springer Science and Business Media LLC
Published: 2019-12-12
Volume: 16
Issue: 1
Pages: 9-29
ISSN: 1759-4758 (ISSN-L)
1759-4766
DOI: 10.1038/s41582-019-0284-z
OpenAlex: W2996080671
Cited by: 970
References: 351
Citations by year: 2026: 79 · 2025: 126 · 2024: 173 · 2023: 185 · 2022: 183 · 2021: 142 · 2020: 82
FWCI: 13.33
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Reviews Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
Keywords: cannabinoids, endocannabinoid system, endocannabinoidome, neurological disorders, CB1 receptor, CB2 receptor, nabiximols, cannabidiol, THC, multiple sclerosis, spasticity, neuropathic pain, pediatric epilepsy, Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, stroke, glioblastoma
MeSH terms: Analgesics, Animals, Cannabidiol, Cannabinoids, Drug Combinations, Humans, Nervous System Diseases, Dronabinol, Receptor, Cannabinoid, CB1, Receptor, Cannabinoid, CB2, Endocannabinoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cannabinoids and the expanded endocannabinoid system in neurological disorders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks